These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15532993)

  • 21. Modulating vaccine responses with dendritic cells and Toll-like receptors.
    Pulendran B
    Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacterial CpG-DNA licenses TLR9.
    Bauer S; Wagner H
    Curr Top Microbiol Immunol; 2002; 270():145-54. PubMed ID: 12467249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Toll-like receptor recognizes bacterial DNA.
    Hemmi H; Takeuchi O; Kawai T; Kaisho T; Sato S; Sanjo H; Matsumoto M; Hoshino K; Wagner H; Takeda K; Akira S
    Nature; 2000 Dec; 408(6813):740-5. PubMed ID: 11130078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accessing the therapeutic potential of immunostimulatory nucleic acids.
    Barchet W; Wimmenauer V; Schlee M; Hartmann G
    Curr Opin Immunol; 2008 Aug; 20(4):389-95. PubMed ID: 18652893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
    Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
    J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
    Ishii KJ; Gursel I; Gursel M; Klinman DM
    Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
    Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
    Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing immunogenicity by CpG DNA.
    Jiang W; Pisetsky DS
    Curr Opin Mol Ther; 2003 Apr; 5(2):180-5. PubMed ID: 12772509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity.
    Peter M; Bode K; Lipford GB; Eberle F; Heeg K; Dalpke AH
    Immunology; 2008 Jan; 123(1):118-28. PubMed ID: 17961163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.
    Babiuk S; Mookherjee N; Pontarollo R; Griebel P; van Drunen Littel-van den Hurk S; Hecker R; Babiuk L
    Immunology; 2004 Sep; 113(1):114-20. PubMed ID: 15312142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stimulatory type A CpG-DNA induces a Th2-like response in human endothelial cells.
    Fitzner N; Zahner L; Habich C; Kolb-Bachofen V
    Int Immunopharmacol; 2011 Nov; 11(11):1789-95. PubMed ID: 21820085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of CpG oligodeoxynucleotides as immunoprotective agents.
    Klinman DM
    Expert Opin Biol Ther; 2004 Jun; 4(6):937-46. PubMed ID: 15174975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species.
    Manuja A; Manuja BK; Kaushik J; Singha H; Singh RK
    Immunopharmacol Immunotoxicol; 2013 Oct; 35(5):535-44. PubMed ID: 23981003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of CpG oligodeoxynucleotides in veterinary species.
    Ioannou XP; Griebel P; Mena A; Gomis SM; Godson DL; Mutwiri G; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):157-67. PubMed ID: 12954116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery of potent immunostimulatory CpG-ODNs widely distributed in bacterial genomes.
    Liu J; Wei Y; Lu Y; Li Y; Chen Q; Li Y
    J Microbiol; 2020 Feb; 58(2):153-162. PubMed ID: 31872374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CpG DNA in the prevention and treatment of infections.
    Dalpke A; Zimmermann S; Heeg K
    BioDrugs; 2002; 16(6):419-31. PubMed ID: 12463765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CpG DNA: recognition by and activation of monocytes.
    Klinman DM; Takeshita F; Gursel I; Leifer C; Ishii KJ; Verthelyi D; Gursel M
    Microbes Infect; 2002 Jul; 4(9):897-901. PubMed ID: 12106782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways.
    Yasuda K; Yu P; Kirschning CJ; Schlatter B; Schmitz F; Heit A; Bauer S; Hochrein H; Wagner H
    J Immunol; 2005 May; 174(10):6129-36. PubMed ID: 15879108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of Mitochondrial Transcription Factor A Attenuation of CpG-Induced Antibody Production.
    Malarkey CS; Gustafson CE; Saifee JF; Torres RM; Churchill ME; Janoff EN
    PLoS One; 2016; 11(6):e0157157. PubMed ID: 27280778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.